Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

I2286

Sigma-Aldrich

Irbesartan

≥98% (HPLC), powder

Sinônimo(s):

2-Butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one, Avapro, BMS-186295, SR-47436

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C25H28N6O
Número CAS:
138402-11-6
Peso molecular:
428.53
Número MDL:
MFCD00864464
Código UNSPSC:
12352200
ID de substância PubChem:
329815365
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to off-white

solubilidade

DMSO: >25 mg/mL

originador

Bristol-Myers Squibb
Sanofi Aventis

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5nnn[nH]5

InChI

1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

chave InChI

YOSHYTLCDANDAN-UHFFFAOYSA-N

Informações sobre genes

human ... AGTR1(185)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

Irbesartan comprises bipentyl-tetrazole side chain. It is an imidazole derivative with high bioavailability and is metabolized by the enzyme cytochrome P450 2C9 isoenzyme in liver to be majorly eliminated by oxidation and glucuronidation.

Aplicação

Irbesartan has been used as an angiotensin II receptor type 1 (ATR1) blocker in carotid atheroma tissue. It may be used to test its effect on allergic asthma in rat and mice mast cells.

Ações bioquímicas/fisiológicas

Irbesartan is an angiotensin II type 1 (AT1) receptor antagonist with antihypertensive activity. It also elicits selective peroxisome proliferator-activated receptor γ (PPARγ)-modulating activity and possesses anti-inflammatory properties. Irbesartan shows protective cardiovascular effects and provides protection against chronic glomerulonephritis.

Características e benefícios

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb and Sanofi Aventis. To browse the list of other pharma-developed compounds, Approved Drugs, and Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
017M4707V
102M4732V
031M4728V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 8

1 of 8

Irbesartan impurity A European Pharmacopoeia (EP) Reference Standard

Y0001156

Irbesartan impurity A

Azilsartan ≥98% (HPLC)

Sigma-Aldrich

SML0432

Azilsartan

Valsartan British Pharmacopoeia (BP) Reference Standard

BP1161

Valsartan

Ambrisentan ≥98% (HPLC)

Sigma-Aldrich

SML2104

Ambrisentan

Enalaprilat dihydrate ≥98% (HPLC)

Sigma-Aldrich

E9658

Enalaprilat dihydrate

Olmesartana medoxomila ≥98% (HPLC)

Sigma-Aldrich

SML1391

Olmesartana medoxomila

Valsartan Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1315

Valsartan

Losartan Potassium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1602

Losartan Potassium

I Van Liefde et al.
Molecular and cellular endocrinology, 302(2), 237-243 (2008-07-16)
Sartans are non-peptide AT(1) receptor antagonists used to treat hypertension and related pathologies. Their effects on the G protein-dependent responses of angiotensin II (Ang II) were the same in vascular tissues and in isolated cell systems. All are competitive but
Marie Hudson et al.
Pharmacotherapy, 27(4), 526-534 (2007-03-27)
To examine the class effect of angiotensin II receptor blockers (ARBs) on mortality in patients with heart failure who were aged 65 years or older. Retrospective population-based study. Administrative database that stores information on hospital discharge summaries for the Canadian
Guru Prasad Sharma et al.
International journal of radiation oncology, biology, physics, 113(1), 177-191 (2022-01-31)
Radiation-induced lung injury is a major dose-limiting toxicity for thoracic radiation therapy patients. In experimental models, treatment with angiotensin converting enzyme (ACE) inhibitors mitigates radiation pneumonitis; however, the mechanism of action is not well understood. Here, we evaluate the direct
David V Erbe et al.
Vascular pharmacology, 45(3), 154-162 (2006-06-13)
Elevated blood pressure and insulin resistance are strongly associated in patients. We explored the potential for the anti-hypertensive angiotensin II type 1-receptor (ATR(1)) antagonists to improve insulin sensitivity through modulation of the nuclear receptor PPARgamma, in vitro and in vivo
Zhongqi Dong et al.
Molecular pharmaceutics, 10(3), 1008-1019 (2013-01-24)
The hepatic bile acid uptake transporter sodium taurocholate cotransporting polypeptide (NTCP) is less well characterized than its ileal paralog, the apical sodium dependent bile acid transporter (ASBT), in terms of drug inhibition requirements. The objectives of this study were (a)
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica